Transformational therapies for the treatment of cardiovascular diseases

Learn More

Addressing Unmet Cardiovascular Needs

Orchestra BioMed is a therapeutic device company focused on the development and commercialization of high impact, data-driven, transformational solutions for targeted high value unmet medical needs. Our main focus is on developing new therapies for cardiovascular diseases which are the leading cause of death worldwide, taking the lives of 17.7 million people each year or 31% of all global deaths according to the World Health Organization. Cardiovascular diseases are the leading cause of death in the U.S. as well, causing 774,165 deaths or over 28.5% of all deaths in 2015 according to the CDC. Despite medical advancements, there remains significant need for improvement in clinical outcomes associated with cardiovascular disease.

[   17.7M people die every year from cardiovascular diseases   ]

Product Pipeline Overview

Product pipeline targets large initial markets with significant growth opportunities in expansion future indications.

Learn More

Transformational Therapies for Artery Disease & Hypertension

Innovative therapies target clear unmet needs in high risk patients

News & Events

Orchestra BioMed™ Announces Presentation of Positive 2-Year Clinical Results and Program Update for BackBeat® Cardiac Neuromodulation Therapy at TCT 2018

September 25, 2018

Immediate, Substantial, and Sustained Reduction in Blood Pressure Demonstrates Potential to Offer Highly Differentiated, Breakthrough Treatment for Hypertension

San Diego, CA., September 25, 2018 - Orchestra BioMed, Inc. (“Orchestra BioMed” or the “Company”), a biomedical innovation company developing transformational therapeutic devices targeting major medical conditions, presented positive 2-year clinical results from its multicenter clinical trial for BackBeat® Cardiac Neuromodulation Therapy (CNT) at the Transcatheter Cardiovascular Therapeutics (TCT) 2018 in San Diego, CA. Daniel Burkhoff, M.D., Ph.D., Director, Heart Failure, Hemodynamics and Mechanical Circulatory Support Research for the Cardiovascular Research Foundation, presented clinical outcomes of the Moderato I Study, which demonstrated immediate, substantial and sustained reduction in blood pressure when BackBeat CNT was used in patients with persistent hypertension (office BP > 150mmHg) despite two or more anti-hypertensive medications and an indication for a pacemaker.

Orchestra BioMed™ Announces Presentation of 3-Year Clinical Results for Virtue® Sirolimus-Eluting Balloon at TCT 2018

September 24, 2018

Excellent Long-Term Safety and Efficacy Profile Demonstrate Potential to Offer Valuable New Treatment for Coronary In-Stent Restenosis

San Diego, CA., September 24, 2018 - Orchestra BioMed, Inc. (“Orchestra BioMed” or the “Company”), a biomedical innovation company developing transformational therapeutic devices targeting major medical conditions, announced the 3-year clinical results from its Sirolimus Angioplasty Balloon for In-Stent Restenosis (SABRE) Trial at the Transcatheter Cardiovascular Therapeutics (TCT) 2018 in San Diego, CA. Juan Granada, M.D., Associate Professor of Medicine at the Columbia University College of Physicians and Surgeons and President and CEO of Cardiovascular Research Foundation, presented the outcomes of SABRE trial, which demonstrated excellent efficacy and safety performance of the Virtue® Sirolimus-Eluting Balloon (SEB) in a very challenging patient population with predominantly long, diffuse restenosis lesions within stents that had been implanted an average of nearly 4 years prior to the study enrollment. The primary safety and efficacy per protocol endpoint results of the study were as follows:

Read All News